Mycophenolic Acid Shortage: What Providers and Prescribers Need to Know in 2026

Mycophenolic acid—administered as mycophenolate mofetil (CellCept) or mycophenolate sodium delayed-release (Myfortic)—is a foundational immunosuppressant in solid organ transplantation. As prescribing volumes continue to grow alongside record transplant rates, clinicians must be prepared for the possibility of localized supply disruptions. This guide provides a clinical overview of the availability landscape, formulation considerations, and evidence-based management strategies for 2026.

Current Availability Status in 2026

As of 2026, mycophenolate mofetil (MMF) is not in an active FDA-declared nationwide shortage. The generic market is robust, with multiple manufacturers including Teva, Sandoz, Hikma, Accord, Ascend, and Mylan/Viatris supplying the U.S. market. The proprietary brand CellCept (Roche/Genentech) and generic oral suspension Myhibbin (Azurity Pharmaceuticals, FDA-approved 2024) also remain available.

Mycophenolate sodium delayed-release tablets (Myfortic/generic EC-MPS) have a more limited generic manufacturer base and have experienced ASHP-tracked shortages in the past. Clinicians should be aware that patients prescribed this formulation may face greater difficulty sourcing it at certain pharmacy chains.

Clinical Formulation Distinctions: MMF vs. EC-MPS

A critical clinical point: mycophenolate mofetil (MMF) and enteric-coated mycophenolate sodium (EC-MPS, Myfortic) are not bioequivalent and cannot be substituted on a milligram-for-milligram basis. Prescribers must be explicit on prescriptions to avoid substitution errors.

Dose equivalence: 720 mg EC-MPS ≈ 1,000 mg MMF on a mole-to-mole basis. For patients on the standard kidney transplant regimen: MMF 1 g BID ≈ EC-MPS 720 mg BID.

Absorption timing: MMF is absorbed in the stomach (Tmax 0.5–1.0 h); EC-MPS is designed to release in the intestine (Tmax 1.5–2.75 h) to reduce upper GI side effects. This means EC-MPS can be taken with or without food, while standard MMF is typically taken on an empty stomach.

FDA approval scope: MMF is approved for kidney, heart, and liver transplants; EC-MPS (Myfortic) is approved only for kidney transplant prevention in adults, and for pediatric kidney transplant patients 5 years and older.

Evidence-Based Alternatives When Mycophenolate Is Unavailable

If a patient cannot obtain their mycophenolate formulation, consider the following evidence-based alternatives:

Switch to the other mycophenolate formulation: If EC-MPS is unavailable, converting to MMF at the appropriate dose equivalent (720 mg EC-MPS → 1,000 mg MMF) is the most straightforward clinical option. Requires physician supervision and patient education.

Azathioprine (AZA): The original antimetabolite immunosuppressant; widely available and less costly. Multiple registrational trials showed MMF superior to AZA in preventing acute rejection at 6 months post-transplant; however, AZA may be appropriate as a bridge or for stable long-term patients. TPMT testing is recommended before initiation. Do not combine with MMF/EC-MPS (additive toxicity, no synergy).

mTOR inhibitors (sirolimus, everolimus): May be considered in selected patients, particularly where CNI-sparing regimens are warranted or malignancy risk is a concern. Not appropriate for early post-transplant use due to impaired wound healing; requires therapeutic drug monitoring.

REMS Requirements and Prescriber Obligations

The FDA mandates a Risk Evaluation and Mitigation Strategy (REMS) for mycophenolate products, primarily focused on preventing embryofetal toxicity. As a prescriber, your REMS obligations include:

Counseling female patients of reproductive potential about the mandatory REMS requirements including pregnancy testing and contraception

Pregnancy testing (negative result required) before initiating therapy and repeated at routine follow-up

Discussing acceptable contraception methods; note that mycophenolate reduces the efficacy of hormonal contraceptives and additional barrier methods are required

Encouraging pregnant patients who were exposed to register with the Mycophenolate Pregnancy Registry (1-800-617-8191)

Patient Communication Strategies During Supply Disruptions

When a patient contacts your office because they cannot fill their mycophenolate prescription, a structured response protocol helps:

Triage urgency — how many doses does the patient have remaining?

Contact the patient's pharmacy directly to understand the expected availability timeline

Identify and contact your institution's preferred specialty pharmacy for emergency supply

If formulation switch is needed, write the new prescription clearly specifying drug name, formulation type, strength, and frequency

Recommend medfinder to patients — this service calls pharmacies in the patient's area to locate which ones have the medication in stock

Monitoring Considerations When Changing Formulations

When converting patients between MMF and EC-MPS formulations, or to an alternative agent, closer monitoring is warranted:

Complete blood count (CBC) within 2–4 weeks of formulation change (monitor for cytopenias)

Serum creatinine and urinalysis to assess graft function

Calcineurin inhibitor trough levels may be affected if concomitant cyclosporine is being used (cyclosporine inhibits enterohepatic recirculation of MPA)

For a comprehensive provider guide on helping patients locate this medication, visit medfinder for providers or read How to Help Your Patients Find Mycophenolic Acid in Stock.